This project proposes the mining of plasma and cerebrospinal fluid (CSF) biomarkers of disease progression in Huntington Disease (HD) using the latest analytical tools to accelerate future treatment studies.
Tracking the onset and progression of HD using molecular biomarkers would be a desired, practical and inexpensive tool that can strongly compliment clinical and physiological measures and that would provide valuable information for clinical decision-making and drug development for the HD community. Since there are both peripheral and central nervous system (CNS) manifestations of the disease that can provide for biomarkers, we propose to include cerebral spinal fluid (CSF), in addition to the current plasma collection.
|Paulsen, Jane S; Long, Jeffrey D (2014) Onset of Huntington's disease: can it be purely cognitive? Mov Disord 29:1342-50|